Showing results (401-410 of 530) with videos related to
Sort By:
Pageof 53
Plos One|January 30, 2019
Cost minimization analysis of line probe assay for detection of multidrug-resistant tuberculosis in Arkhangelsk region of Russian FederationE N Bogdanova, A O Mariandyshev, G A Balantcev, et al.Diagnostics (Basel, Switzerland)|June 2, 2019
Feasibility of Direct Sputum Molecular Testing for Drug Resistance as Part of Tuberculosis Clinical Trials Eligibility ScreeningNarges Alipanah, Priya B Shete, Hanh Nguyen, et al.European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|January 27, 2012
Specific protease activity indicates the degree of Pseudomonas aeruginosa infection in chronic infected woundsD Wildeboer, K E Hill, F Jeganathan, et al.The Journal of Clinical Endocrinology and Metabolism|May 20, 1998
Immortalized human pituitary cells express glycoprotein alpha-subunit and thyrotropin beta (TSH beta)J Ham, J Webster, J A Bond, et al.Prenatal Diagnosis|August 9, 2001
Karyotypes found in the population declared at increased risk of Down syndrome following maternal serum screeningR G Ryall, D Callen, R Cocciolone, et al.Journal of Clinical Microbiology|February 4, 2021
Mycobactericidal Effects of Different Regimens Measured by Molecular Bacterial Load Assay among People Treated for Multidrug-Resistant Tuberculosis in TanzaniaPeter M Mbelele, Emmanuel A Mpolya, Elingarami Sauli, et al.The Journal of Antimicrobial Chemotherapy|October 27, 2014
The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populationsRuth Bowness, Martin J Boeree, Rob Aarnoutse, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 13, 2026
When are uncontrolled trials in TB scientifically and ethically justified: Borrowing wisdom from early AIDS clinical trialsLindsay McKenna, Mike Frick, Valentina A Alarcón-Guizado, et al.The European Respiratory Journal|February 5, 2021
Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg-1 rifampicinLindsey H M Te Brake, Veronique de Jager, Kim Narunsky, et al.The Lancet. Global Health|January 20, 2024
Evaluation of the Xpert MTB Host Response assay for the triage of patients with presumed pulmonary tuberculosis: a prospective diagnostic accuracy study in Viet Nam, India, the Philippines, Uganda, and South AfricaAnkur Gupta-Wright, Huy Ha, Shima Abdulgadar, et al.Pageof 53